Cymbalta not to be used with MAOIs

Thread view:

Enable EMail Alerts

Start New Thread

Thread rating:

Uncle Enrico - 19 Mar 2008 19:01 GMT

On November 28, 2007, the FDA approved safety labeling revisions for
duloxetine HCl delayed-release capsules (Cymbalta; Eli Lilly and Co) to
emphasize that monoamine oxidase inhibitors (MAOIs) should not be used
concomitantly or in close temporal proximity to selective serotonin
reuptake inhibitors (SSRIs).

Reply to this Message

Herman Rubin - 21 Mar 2008 03:06 GMT

>On November 28, 2007, the FDA approved safety labeling revisions for
>duloxetine HCl delayed-release capsules (Cymbalta; Eli Lilly and Co) to
>emphasize that monoamine oxidase inhibitors (MAOIs) should not be used
>concomitantly or in close temporal proximity to selective serotonin
>reuptake inhibitors (SSRIs).

There is nothing new about such warnings about
interactions. I am taking a SSRI, and tried a still
different one before having to give it up because of
side effects, and they both had this warning.

Signature

This address is for information only. I do not claim that these views
are those of the Statistics Department or of Purdue University.
Herman Rubin, Department of Statistics, Purdue University
hrubin@stat.purdue.edu Phone: (765)494-6054 FAX: (765)494-0558

Reply to this Message